TNXP - トニックス・ファ―マシュ―ティカルズ (Tonix Pharmaceuticals Holding Corp.)

TNXPのニュース

   Benzinga Global Small Cap Conference Day 2 Recap: Ideanomics, LiveXLive, EVs And Much More  2020/12/09 23:31:13 Benzinga
The inaugural Benzinga Global Small Cap Conference wrapped up Wednesday with another day of coverage on small cap stocks from CEOs and industry experts. Be sure to check the Benzinga Events page for more upcoming exclusive events. Company Presentations: Below are some of the highlights: Yatra Online (NASDAQ: YTRA ) highlighted its position as the leading brand in India for the travel market. The company has 11 million accumulated customers and is seeing COVID-19 cases declining in the country. Ideanomics (NASDAQ: IDEX ) highlighted its electric vehicle and fintech subsidiaries. CEO Alf Poor said the King of Malaysia is invested in one of the company subsidiaries. The company plans on entering the commercial fleet market and selling school buses in Europe. Tonix Pharmaceuticals (NASDAQ: TNXP ) highlighted its CNS and immunology treatment options. The company is planning on submitting an NDA for its fibromyalgia candidate in 2021. The company also highlighted a COVID-19 treatment option that could progress further in the first quarter of 2021.
   Tonix Pharmaceuticals (TNXP) Could Be a Come-From-Behind Vaccine Shocker | EmergingGrowth.com  2020/10/27 13:01:06 Emerging Growth
Tonix Pharmaceuticals (TNXP) Could Be a Come-From-Behind Vaccine Shocker Among small-capitalization companies in the Covid-19 race, Tonix Pharmaceuticals (NASDAQ:TNXP) may be worth consideration with what I would term “dumb money.” Currently, TNXP stock is trading hands for less than a buck, which immediately tells you something about this opportunity’s risk profile.
   Zacks: Analysts Expect Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) to Announce -$0.11 EPS  2020/10/23 15:18:53 The Olympia Report
Wall Street brokerages predict that Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) will post earnings per share of ($0.11) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Tonix Pharmaceuticals’ earnings. Tonix Pharmaceuticals reported earnings of ($5.69) per share in the same quarter last year, which would indicate a positive year-over-year growth […]
   Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) Expected to Post Earnings of -$0.11 Per Share  2020/10/23 14:19:01 US Banking News
Wall Street brokerages predict that Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) will post earnings per share of ($0.11) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Tonix Pharmaceuticals’ earnings. Tonix Pharmaceuticals reported earnings of ($5.69) per share in the same quarter last year, which would indicate a positive year-over-year growth […]
   Tonix Pharmaceuticals (NASDAQ:TNXP) Trading Down 7.1%  2020/10/21 19:38:41 The Olympia Report
Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP)’s share price dropped 7.1% during trading on Wednesday . The stock traded as low as $0.64 and last traded at $0.65. Approximately 6,759,833 shares were traded during mid-day trading, a decline of 48% from the average daily volume of 12,975,604 shares. The stock had previously closed at $0.70. Separately, Alliance […]
   Tonix Pharmaceuticals (TNXP) Could Be a Come-From-Behind Vaccine Shocker | EmergingGrowth.com  2020/10/27 13:01:06 Emerging Growth
Tonix Pharmaceuticals (TNXP) Could Be a Come-From-Behind Vaccine Shocker Among small-capitalization companies in the Covid-19 race, Tonix Pharmaceuticals (NASDAQ:TNXP) may be worth consideration with what I would term “dumb money.” Currently, TNXP stock is trading hands for less than a buck, which immediately tells you something about this opportunity’s risk profile.
   Zacks: Analysts Expect Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) to Announce -$0.11 EPS  2020/10/23 15:18:53 The Olympia Report
Wall Street brokerages predict that Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) will post earnings per share of ($0.11) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Tonix Pharmaceuticals’ earnings. Tonix Pharmaceuticals reported earnings of ($5.69) per share in the same quarter last year, which would indicate a positive year-over-year growth […]
   Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) Expected to Post Earnings of -$0.11 Per Share  2020/10/23 14:19:01 US Banking News
Wall Street brokerages predict that Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) will post earnings per share of ($0.11) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Tonix Pharmaceuticals’ earnings. Tonix Pharmaceuticals reported earnings of ($5.69) per share in the same quarter last year, which would indicate a positive year-over-year growth […]
   Tonix Pharmaceuticals (NASDAQ:TNXP) Trading Down 7.1%  2020/10/21 19:38:41 The Olympia Report
Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP)’s share price dropped 7.1% during trading on Wednesday . The stock traded as low as $0.64 and last traded at $0.65. Approximately 6,759,833 shares were traded during mid-day trading, a decline of 48% from the average daily volume of 12,975,604 shares. The stock had previously closed at $0.70. Separately, Alliance […]
   With Key Data Nearing, Tonix Looks to Spotlight Robust Pipeline In Immunology And CNS Therapeutics  2020/08/26 11:21:06 Benzinga
The following article is sponsored by the clinical communications unit of Redington, Inc. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational purposes only. Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP ) has been operating under the radar of major institutional investors, but that may soon change. After a series of near misses in a handful of clinical trial programs, the company is closing in on data from two important programs. Positive readouts from either one promises to spotlight the company’s diverse portfolio built on unmet needs in billion-dollar medical categories. Before yearend, Tonix expects to release data from advanced non-human primate studies of its lead Covid-19 T cell eliciting vaccine candidate utilizing live attenuated virus vectors. Vaccines made with attenuated viruses are known to confer long term immunity with a single dose (think vaccines for smallpox, measles, mumps and rubella) – and they are the only ones known to prevent forward transmission or contagion.
   With Key Data Nearing, Tonix Looks to Spotlight Robust Pipeline In Immunology And CNS Therapeutics  2020/08/26 11:21:06 Benzinga
The following article is sponsored by the clinical communications unit of Redington, Inc. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational purposes only. Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP ) has been operating under the radar of major institutional investors, but that may soon change. After a series of near misses in a handful of clinical trial programs, the company is closing in on data from two important programs. Positive readouts from either one promises to spotlight the company’s diverse portfolio built on unmet needs in billion-dollar medical categories. Before yearend, Tonix expects to release data from advanced non-human primate studies of its lead Covid-19 T cell eliciting vaccine candidate utilizing live attenuated virus vectors. Vaccines made with attenuated viruses are known to confer long term immunity with a single dose (think vaccines for smallpox, measles, mumps and rubella) – and they are the only ones known to prevent forward transmission or contagion.
   Insider Buys Tonix Pharmaceuticals Shares  2020/08/24 11:37:00 Benzinga
Bell Margaret Smith filed a Form 4 with the SEC on Monday, August 24. The insider bought 5,391 shares of Tonix Pharmaceuticals Inc (NASDAQ:TNXP) at an …
   Tonix Pharmaceuticals Reports Second Quarter 2020 Financial Results and Operational Highlights  2020/08/10 12:45:00 GlobeNewswire
Preclinical data for TNX-1800, a Vaccine Candidate to Protect Against COVID-19, Expected in Fourth Quarter 2020 Interim Analysis Results for Phase…
   Tonix Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement  2020/08/04 13:00:00 GlobeNewswire
NEW YORK, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical…
   Tonix Pharmaceuticals Holding Corp. Announces Rescheduling of Special Meeting of Stockholders  2020/07/21 20:45:00 GlobeNewswire
NEW YORK, July 21, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical…

calendar